第二層分類
Pipeline
Chiron01, our pioneering UMSCs (allogeneic umbilical cord mesenchymal stem cells), ChironPharma's groundbreaking new drug in development, is derived from allogeneic cells that can be produced and stored in advance, readily available for use when needed (off-the-shelf availability). Moreover, this product is formulated without the use of animal serum, incorporating a specialized cell culture formula. This approach mitigates the risk of infections and allergies associated with animal serum cultures while simultaneously enhancing the proliferation and differentiation capabilities of stem cells.
Chiron01 is primarily intended for critical medical conditions, including Acute Myocardial Infarction (AMI), acute ischemic stroke, multiple sclerosis, Diabetes mellitus (DM) and Amyotrophic Lateral Sclerosis (ALS).
In addition, our commitment to research and development encompasses technologies associated with Chiron02, including cRBC (cultured red blood cells), and genetically engineered mesenchymal stem cells. These areas hold significant promise for future advancements and breakthroughs in our field.
Chiron01 is primarily intended for critical medical conditions, including Acute Myocardial Infarction (AMI), acute ischemic stroke, multiple sclerosis, Diabetes mellitus (DM) and Amyotrophic Lateral Sclerosis (ALS).
In addition, our commitment to research and development encompasses technologies associated with Chiron02, including cRBC (cultured red blood cells), and genetically engineered mesenchymal stem cells. These areas hold significant promise for future advancements and breakthroughs in our field.